Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia

被引：30
|
作者：
Khalili, Hossein [1 ]
Shojaei, Lida [2 ]
Mohammadi, Mostafa [3 ]
Beigmohammadi, Mohammad-Taghi [3 ]
Abdollahi, Alireza [4 ]
Doomanlou, Mahsa [5 ]
机构：
[1] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran
[2] Kermanshah Univ Med Sci, Fac Pharm, Dept Clin Pharm, Kermanshah, Iran
[3] Univ Tehran Med Sci, Imam Khomeini Hosp, Fac Med, Dept Intens Care Unit, Tehran, Iran
[4] Univ Tehran Med Sci, Imam Khomeini Hosp, Fac Med, Dept Pathol, Tehran, Iran
[5] Univ Tehran Med Sci, Cent Lab, Imam Hosp Complex, Tehran, Iran
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 09期
关键词：
Acinetobacter; ampicillin-sulbactam; colistin; pneumonia; VENTILATOR-ASSOCIATED PNEUMONIA; ACINETOBACTER-BAUMANNII; NOSOCOMIAL PNEUMONIA; AMPICILLIN-SULBACTAM; INTRAVENOUS COLISTIN; RISK-FACTORS; POLYMYXIN-B; MORTALITY; SURVEILLANCE; INFECTIONS;
D O I：
10.2217/cer-2018-0037
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: Efficacy of colistin and ampicillin-sulbactam have not been compared in treatment of ventilator-associated pneumonia due to A. baumannii. Efficacy of colistin and ampicillin-sulbactam in combination with meropenem were compared in treatment of ventilator-associated pneumonia due to carbapenem-resistant A. baumannii. Method: 47 patients with ventilator-associated pneumonia due to carbapenem-resistant A. baumannii were randomized to receive meropenem/colistin or meropenem/ampicillin-sulbactam for 14 days. Clinical and microbiological responses and 28-day mortality were considered as outcomes. Results: Clinical response (75 vs 69.6%; p = 0.75) and microbial eradication (87.50 vs 91.3%; p = 0.59) were comparable between meropenem/colistin and meropenem/ampicillin-sulbactam groups, respectively. Conclusion: In this study, clinical and microbiological response were comparable between the meropenem/colistin and meropenem/ampicillin-sulbactam groups.
引用
收藏
页码：901 / 911
页数：11
相关论文
共 50 条
  • [31] Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
    Mona Shaban E. M. Badawy
    Walid F. Elkhatib
    Rania I. Shebl
    Annals of Clinical Microbiology and Antimicrobials, 22
  • [32] Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
    Petty, Lindsay A.
    Henig, Oryan
    Patel, Twisha S.
    Pogue, Jason M.
    Kaye, Keith S.
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 1461 - 1472
  • [33] Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
    Badawy, Mona Shaban E. M.
    Elkhatib, Walid F.
    Shebl, Rania I.
    ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2023, 22 (01)
  • [34] In Vitro Evaluation of Synergy in Carbapenem-resistant Klebsiella pneumoniae Strains with Antibiotic Combinations of Meropenem, Fosfomycin, Colistin, and Tigecycline
    KandemIr, Ozlem
    Oksuz, Zehra
    Delialioglu, Nuran
    Aslan, Dogan Can
    SerIn, Mehmet Sami
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2021, 10
  • [35] Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii
    Mohd Sazlly Lim, Sazlyna
    Heffernan, Aaron J.
    Zowawi, Hosam M.
    Roberts, Jason A.
    Sime, Fekade B.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021, 40 (09) : 1943 - 1952
  • [36] Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii
    Sazlyna Mohd Sazlly Lim
    Aaron J. Heffernan
    Hosam M. Zowawi
    Jason A. Roberts
    Fekade B. Sime
    European Journal of Clinical Microbiology & Infectious Diseases, 2021, 40 : 1943 - 1952
  • [37] Metabolomics Method in Understanding and Sensitizing Carbapenem-Resistant Acinetobacter baumannii to Meropenem
    Li, Xia
    Feng, Dingyun
    Zhou, Jianxia
    Wu, Wenbin
    Zheng, Wenzheng
    Gan, Wenlei
    Jiang, Ming
    Li, Hui
    Peng, Xuanxian
    Zhang, Tiantuo
    ACS INFECTIOUS DISEASES, 2023, 10 (01): : 184 - 195
  • [38] Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae
    Jorgensen, Sarah Christina Jane
    Rybak, Michael Joseph
    PHARMACOTHERAPY, 2018, 38 (04): : 444 - 461
  • [39] Effect of Meropenem Concentration on the Detection of Low Numbers of Carbapenem-Resistant Enterobacteriaceae
    Tanner, Windy D.
    Atkinson, Robyn M.
    Goel, Ramesh K.
    Porucznik, Christina A.
    Benson, Lowell Scott
    VanDerslice, James A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (01) : 712 - 713
  • [40] Exogenous glutathione reverses meropenem resistance in carbapenem-resistant Klebsiella pneumoniae
    Yi, Juan
    Liu, Chao
    Yang, Ping
    Wu, Zhen-chao
    Du, Chun-jing
    Shen, Ning
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345